Stoke Therapeutics Sees Unusually Large Options Volume (NASDAQ:STOK)

Stoke Therapeutics, Inc. (NASDAQ:STOK) was the target of some unusual options trading on Friday. Investors bought 10,008 call options on the stock. This is an increase of approximately 1,407% compared to the typical volume of 664 call options.

Analyst Ratings Changes

A number of brokerages have weighed in on STOK. Canaccord Genuity Group boosted their price target on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a report on Monday, November 3rd. Needham & Company LLC boosted their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Chardan Capital raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $31.00.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 45,996 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.13, for a total transaction of $925,899.48. Following the transaction, the director owned 91,585 shares in the company, valued at $1,843,606.05. This represents a 33.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Jonathan Allan sold 14,922 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $20.14, for a total transaction of $300,529.08. Following the transaction, the general counsel owned 18,176 shares in the company, valued at $366,064.64. This represents a 45.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 213,367 shares of company stock worth $5,110,464. Corporate insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Generali Investments Management Co LLC acquired a new stake in Stoke Therapeutics during the third quarter worth about $41,000. BNP Paribas Financial Markets lifted its holdings in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares in the last quarter. AlphaQuest LLC acquired a new stake in shares of Stoke Therapeutics during the 1st quarter worth approximately $72,000. Finally, US Bancorp DE increased its stake in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company’s stock valued at $75,000 after acquiring an additional 11,108 shares during the last quarter.

Stoke Therapeutics Stock Up 5.0%

STOK opened at $29.34 on Friday. The stock’s 50 day moving average price is $27.53 and its two-hundred day moving average price is $18.42. Stoke Therapeutics has a 12-month low of $5.35 and a 12-month high of $38.69. The firm has a market capitalization of $1.68 billion, a P/E ratio of 43.79 and a beta of 1.32.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The company had revenue of $10.63 million during the quarter, compared to analyst estimates of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. As a group, analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.